HOPKINTON, Mass., Oct. 7 /PRNewswire/ -- Aderis Pharmaceuticals announced today that the CFO and Chief Commercial Officer, Kenneth Rice Jr., will present a corporate and clinical program update on Thursday, October 14 at 11:10 a.m. (PDT) at the BIO Emerging Company Investor Forum. The forum will take place October 13-15 at the Palace Hotel in San Francisco.
BIO's Emerging Company Investor Forum, hosted by Lazard and Banc of America Securities, and co-hosted by CIBC World Markets, Pacific Growth Equities, and Citigroup, addresses an unmet need identified by the investment community and industry executives for a conference exclusively focused on emerging public and late-stage private companies in the biotechnology industry.
About Aderis Pharmaceuticals
Aderis Pharmaceuticals is a private, biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and inflammatory disorders. The Company currently has five product candidates in nine internal or partnered clinical development programs. Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma AG for the development and commercialization of Neupro(TM) (rotigotine transdermal system), a proprietary dopamine agonist formulated as a once daily, continuous delivery, transdermal patch to treat Parkinson's disease. NDA and MAA applications for the Neupro(TM) patch have been recently filed. Rotigotine has also completed Phase IIb trials for the treatment of Restless Legs Syndrome and a nasal spray formulation is in Phase I testing as a rescue medication for Parkinson's disease. The Company also has development and commercialization collaborations with King Pharmaceuticals. Aderis Pharmaceuticals' product pipeline includes small molecule, receptor agonists and antagonists for the treatment of Parkinson's disease, Restless Legs Syndrome, atrial fibrillation, diabetic foot ulcers, the diagnosis and prognosis of coronary artery disease, and other cardiovascular and renal indications. Founded in 1994, Aderis Pharmaceuticals is headquartered in Hopkinton, Massachusetts and has research facilities in Richmond, Virginia.
Neupro is a trademark of Schwarz Pharma AG.
Certain statements in this news release that are not historical fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Such statements include, but are not limited to, any statements relating to the Company's development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties, including but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization; the uncertainty of patent protection for the Company's intellectual property or trade secrets; and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, some but not all of which may have been mentioned above.
508-497-2300 ext 224
The Ruth Group
CONTACT: Sharon Correia, Aderis Pharmaceuticals, +1-508-497-2300 ext.224, firstname.lastname@example.org; or Cynthia Isaac, The Ruth Group, +1-646-536-7028,email@example.com, for Aderis Pharmaceuticals